| AVP0546 | MWKTPTLKYFGGFNFSQI | 18 | SARS-CoV | 58 | % | Fusion | Plaque assay | 16616792 |
| AVP0547 | ATAGWTFGAGAALQIPFAMQMAY | 23 | SARS-CoV | 39 | % | Fusion | Plaque assay | 16616792 |
| AVP0548 | GYHLMSFPQAAPHGVVFLHVTW | 22 | SARS-CoV | 2 | μM | Fusion | Plaque assay | 16616792 |
| AVP0549 | GVFVFNGTSWFITQRNFFS | 19 | SARS-CoV | 2 | μM | Fusion | Plaque assay | 16616792 |
| AVP0550 | NEVAKNLNESLIDLQELGKYEQYIKWPWYVW | 31 | SARS-CoV | Nil | - | Fusion | Plaque assay | 16616792 |
| AVP0551 | AACEVAKNLNESLIDLQELGKYEQYIKW | 28 | SARS-CoV | 42 | % | Fusion | Plaque assay | 16616792 |
| AVP1477 | FKLPLGINITNFRAILTAFS | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1478 | PTTFMLKYDENGTITDAVDC | 20 | SARS-CoV | 112.5±26.3 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1479 | VLYNSTFFSTFKCYGVSATK | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1480 | PALNCYWPLNDYGFYTTSGI | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1481 | RDVSDFTDSVRDPKTSEILD | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1482 | YQDVNCTDVSTAIHADQLTP | 20 | SARS-CoV | 113.0±27.6 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1483 | SNNTIAIPTNFSISITTEVM | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1484 | QYGSFCTQLNRALSGIAAEQ | 20 | SARS-CoV | 24.9±6.2 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1485 | GIGVTQNVLYENQKQIANQF | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1486 | IQKEIDRLNEVAKNLNESLI | 20 | SARS-CoV | 73.5±15.7 | IC90 (μg/ml) | S protein | Viral titer | US7491489 |
| AVP1583 | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 37 | SARS-CoV | 0.62 | μM | Virus entry | beta-galactosidase activity | 18983873 |
| AVP1584 | GINASVVNIQKEIDRLNEVAKNLNESLIDL | 30 | SARS-CoV | 0.8 | μM | Virus entry | beta-galactosidase activity | 18983873 |
| AVP1585 | GINASVVNIQKEIDRLNEVAKNL | 23 | SARS-CoV | 1.04 | μM | Virus entry | beta-galactosidase activity | 18983873 |
| AVP1586 | QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ | 46 | SARS-CoV | 3.97 | μM | Virus entry | beta-galactosidase activity | 18983873 |
| AVP1587 | QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE | 46 | SARS-CoV | 5.07 | μM | Virus entry | beta-galactosidase activity | 18983873 |
| AVP1641 | KKKKYRNIRRPG | 12 | SARS-CoV | 45 | μg/ml | Virus entry | ELISA | 18383098 |
| AVP1705 | ISGINASVVNIQEEIKKLNEEAKKLNESLIDLQEL | 35 | SARS-CoV | 4 | nM | Virus entry | ELISA | 17942557 |
| AVP1706 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | 35 | SARS-CoV | 5 | nM | Virus entry | ELISA | 17942557 |
| AVP1707 | IEEINKKVEEIQKKIEELNKKAEELNKKLEELQKK | 35 | SARS-CoV | >100 | μM | Virus entry | ELISA | 17942557 |
| AVP1716 | TLKPIFKLPLGINITNFR | 18 | SARS-CoV | 11 | μM | Virus entry | Luciferase assay | 19853613 |
| AVP1717 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | 35 | SARS-CoV | 0.34 | μM(EC50) | Virus entry | Luciferase assay | 18442051 |
| AVP1718 | YENQKQIANQFNKAISQIQESLTTTSTA | 28 | SARS-CoV | 1.16 | μM(EC50) | Virus entry | Luciferase assay | 18442051 |
| AVP1719 | DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI | 48 | SARS-CoV | 2.15 | μM(EC50) | Virus entry | Luciferase assay | 18442051 |
| AVP1720 | IQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSS | 35 | SARS-CoV | ND | μM(EC50) | Virus entry | Luciferase assay | 18442051 |
| AVP1721 | YENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSV | 60 | SARS-CoV | ND | μM(EC50) | Virus entry | Luciferase assay | 18442051 |
| AVP1722 | FGGASCCLYCRCHIDHPNPKGFCDLKGKY | 29 | SARS-CoV | 160 | μM | Replication | MTase Activity Assay | 22659295 |
| AVP1723 | GGASCCLYCRCH | 12 | SARS-CoV | 160 | μM | Replication | MTase Activity Assay | 22659295 |
| AVP1724 | DLKGKYVQIP | 10 | SARS-CoV | Low | μM | Replication | MTase Activity Assay | 22659295 |
| AVP1725 | NCVKMLCTHTGTGQAITVTP | 20 | SARS-CoV | Low | μM | Replication | MTase Activity Assay | 22659295 |
| AVP1726 | PTTCANDP | 8 | SARS-CoV | Low | μM | Replication | MTase Activity Assay | 22659295 |
| AVP1770 | ALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFEL | 33 | SARS-CoV | 41.6 | μM | Virus entry | Plaque assay | 16153058 |
| AVP1822 | YKYRYL | 6 | SARS-CoV | High | - | Virus entry | RT PCR | 22265858 |
| AVP1833 | CANLLLQYGSFCTQLNRALSGIA | 23 | SARS-CoV | 50 | % | Virus entry | Syncitia assay | 15811330 |
| AVP1834 | PSSKRFQPFQQFGRDVSDFT | 20 | SARS-CoV | 50 | % | Virus entry | Syncitia assay | 15811330 |
| AVP1835 | RNTREVFAQVKQMYKTPTLKYFG | 23 | SARS-CoV | Low | - | Virus entry | Syncitia assay | 15811330 |
| AVP1836 | TKFPSVYAWERKKISNCVAD | 20 | SARS-CoV | Low | - | Virus entry | Syncitia assay | 15811330 |
| AVP1837 | KGIYQTSNFRVVPSGDVVRF | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | 15811330 |
| AVP1838 | KSNVVRGWVFGSTMNNKSQS | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | 15811330 |
| AVP1839 | TDAVDCSQNPLAELKCSVKSF | 21 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | 15811330 |
| AVP1840 | TSSMRGVYYPDEIFRSDTLYL | 21 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | 15811330 |
| AVP1841 | YKGYQPIDVVRDLPSGFNTL | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | 15811330 |
| AVP1842 | YNYKYRYLRHGKLRPFERDI | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | 15811330 |
| AVP1857 | NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA | 38 | SARS-CoV | 0.14 | μM(EC50) | Virus entry | Luciferase assay | 15184046 |
| AVP1858 | IQKEIDRLNEVAKNLNESLIDLQELGK | 27 | SARS-CoV | 1.19 | μM(EC50) | Virus entry | Luciferase assay | 15184046 |
| AVP1859 | FNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQL | 40 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1860 | ALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRL | 39 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1861 | IDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATK | 36 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1862 | YVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKG | 40 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1863 | VYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVV | 41 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1864 | QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQ | 39 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1865 | SFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNE | 42 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1866 | LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAK | 40 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1867 | FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES | 41 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1868 | PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQ | 40 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1869 | GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY | 40 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1870 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI KWPW | 47 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1871 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | 37 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1872 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | 35 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1873 | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | 35 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1874 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | 43 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1875 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI | 39 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1876 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | 34 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1877 | INASVVNIQKEIDRLNEVAKNLNESLIDL | 29 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1878 | VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | 39 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1879 | VVNIQKEIDRLNEVAKNLNESLIDLQELGK | 30 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1880 | IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | 36 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1881 | IDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | 32 | SARS-CoV | Low | NA | Virus entry | Luciferase assay | 15184046 |
| AVP1887 | LDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 63 | SARS-CoV | 43±6.4 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1888 | PKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 60 | SARS-CoV | 24±2.8 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1889 | LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 56 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1890 | FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 52 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1891 | TSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 48 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1892 | VDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 44 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1893 | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 40 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1894 | ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK | 68 | SARS-CoV | 17±3.0 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1895 | ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | 60 | SARS-CoV | 34±4.0 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1896 | ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID | 56 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1897 | DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE | 39 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1898 | AYRFNGIQVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT | 96 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1899 | NQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT | 80 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1900 | NQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT | 80 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1901 | NQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT | 46 | SARS-CoV | >50 | μM(EC50) | Fusion | Immunofluorescence | 15150417 |
| AVP1914 | GVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQ | 40 | SARS-CoV | Low | NA | Fusion | Cytopathic effect | 15043961 |
| AVP1915 | LTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFG | 34 | SARS-CoV | No | NA | Fusion | Cytopathic effect | 15043961 |
| AVP1916 | KQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITG | 36 | SARS-CoV | No | NA | Fusion | Cytopathic effect | 15043961 |
| AVP1917 | GRLQSLQTYVTQQLIRAAEIRASANLAATKMSEC | 34 | SARS-CoV | No | NA | Fusion | Cytopathic effect | 15043961 |
| AVP1918 | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 37 | SARS-CoV | 19 | μmol/l | Fusion | Cytopathic effect | 15043961 |
| AVP1919 | KEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVW | 37 | SARS-CoV | No | NA | Fusion | Cytopathic effect | 15043961 |
| AVP2053 | LFGLIPSLIGGLVSAFK | 17 | SARS-CoV | 7.12 | μM(EC50) | Replication | Plaque assay | 21620914 |
| AVP2054 | LFRLIKSLIKRLVSAFK | 17 | SARS-CoV | No | NA | Replication | Plaque assay | 21620914 |
| AVP2055 | SLIGGLVSAFK | 11 | SARS-CoV | No | NA | Replication | Plaque assay | 21620914 |
| AVP2056 | VSAFK | 5 | SARS-CoV | No | NA | Replication | Plaque assay | 21620914 |
